好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparison of Depression and Anxiety in Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis Patients: Analysis of Two National Datasets
Autoimmune Neurology
P11 - Poster Session 11 (5:30 PM-6:30 PM)
14-002
Determine difference in frequency of depression and anxiety diagnoses for patients diagnosed with neuromyelitis optica spectrum disease (NMOSD) compared to patients diagnosed with multiple sclerosis (MS).

NMOSD and MS are both neurological demyelinating diseases. Increased rates of depression and anxiety have been studied in NMOSD and MS and are well documented in progressive illnesses. Historically NMOSD (incidence 1-10/100,000) was considered a rare subvariant of MS (incidence 35.9/100,000) but is now an important differential diagnosis of its own.
NMOSD and MS de-identified aggregate datasets focused on United States patients were obtained from TriNetX, a global research network covering 68 US hospital systems which provides access to clinical patient data. To increase specificity, patients who had less than three NMOSD ICD-10-CM (G36.0) or MS ICD-10-CM (G35) code entries were removed.
Of the 2350 patients with an NMOSD diagnosis, 1806 (76.9%) were female, with a median age of 50.75y [3 - 91]. 586 (24.94%) of NMOSD patients had a depression diagnosis and 527 (22.43%) had an anxiety diagnosis. For the 164969 MS patients, 139168 (84.36%) were female and the median age was 57y [under 1 - 96]. 53524 (32.44%) of MS patients had a depression diagnosis and 46385 (28.12%) had an anxiety diagnosis.

In comparison to NMOSD, MS patients have a higher rate of depression and anxiety diagnoses. Further research is needed to investigate whether this difference is related to the underlying conditions or insufficient screening and documentation of mental health symptoms in NMOSD patients.
Authors/Disclosures
Abigail H. Sorenson
PRESENTER 		Ms. Sorenson has nothing to disclose.
Esther Zeng Miss Zeng has nothing to disclose.
Heewon Hwang No disclosure on file
Tammy L. Smith, MD, PhD (Imaging and Neurosciences Center) Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Smith has received research support from Alexion/AstraZeneca.
Melissa A. Wright, MD (University of Utah) Dr. Wright has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis .
Aditi Sharma (University of Utah) No disclosure on file
Trieste Francis Miss Francis has nothing to disclose.
John W. Rose, MD, FAAN (Imaging and Neurosciences Center) The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Stacey Clardy, MD, PhD, FAAN (University of Utah) Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Beaumont Health, CCF, Emory, Penn State, Mayo Clinic, Walter Reed.